GUAIFENESIN EXTENDE

The contract SPE2DP26F7788, awarded by the Defense Logistics Agency to DMS PHARMACEUTICAL GROUP INC with CAGE code 1UNB0, is a fixed-price delivery order under solicitation SPE2DX25D9900 for the supply of 30 boxes of Guaifenesin Extended Release tablets (NSN 6505017249533) at a unit price of $5.54, resulting in a total contract value of $166.20. Delivery is required by August 4, 2026, to Fort Bragg, North Carolina, with FOB Destination terms placing responsibility on the contractor for shipping and ensuring the product arrives intact for government acceptance at the delivery point. Shipping must occur via the fastest traceable means, explicitly prohibiting parcel post, and all packages must be marked with the NSN, PR number 7017564840, TCN W91KBP60850049, and applicable CAGE codes (1XUY5, 860J1) to ensure traceability within the DoD logistics system. Quantity variance is strictly zero percent, requiring exact fulfillment without tolerance for over or under shipment, and medical substitution is permitted under identifier RANK 01-00536145188 05H9105. The contract is classified under NAICS code 424210, indicating drug and druggist merchant wholesaling, and includes no listed options, modifications, or additional line items beyond the single CLIN. Financial tracking is supported by internal DoD codes DIC A0A and FC Z9, though specific appropriation data, remittance instructions, or invoicing systems such as WAWF are not specified. Inspection and acceptance occur at the destination, with compliance implied for pharmaceutical standards, but no explicit references to MIL-STD packaging, labeling, or quality testing are documented. The awardee’s manufacturer CAGE codes indicate potential sourcing from multiple facilities, and while socioeconomic status and small business certification are not disclosed, the low-dollar value and straightforward nature of the order suggest a Low Price Technically Acceptable award methodology. No formal FAR clauses, evaluation factors, contract administration personnel, or attachment lists are included in the documentation, indicating a minimal administrative footprint typical of small-value pharmaceutical procurements under DLA’s supply chain operations.